Beyond early discovery, LLMs deliver significant value in clinical trials. They accelerate timelines by automating months of post-trial documentation work. More strategically, they can improve trial success rates by analyzing genomic data to identify patient populations with a higher likelihood of responding to a treatment.

AI's most significant impact won't be on broad population health management, but as a diagnostic and decision-support assistant for physicians. By analyzing an individual patient's risks and co-morbidities, AI can empower doctors to make better, earlier diagnoses, addressing the core problem of physicians lacking time for deep patient analysis.

Genomics (DNA/RNA) only provides the 'sheet music' for cancer. Functional Precision Medicine acts as the orchestra, testing how live tumor cells respond to drugs in real time. AI serves as the conductor, optimizing the 'performance' for superior outcomes.

Radiopharmaceuticals can use the same molecular scaffold for diagnosing a tumor with one radionuclide and treating it with another. This "theranostic" strategy improves patient stratification and accelerates the transition from diagnosis to effective therapy.

The future of personalized oncology isn't just about matching one drug to one patient. It's about classifying patients into three key groups: those who respond to everything, those who respond to nothing (and should enter clinical trials), and a crucial middle group where digital twins can identify the specific treatment that will make a difference.

A common mistake in pharma is viewing imaging data solely for its diagnostic value—identifying where a disease is. The greater, untapped potential lies in its predictive value. When made computable, imaging data contains signals about how a disease behaves and will respond to specific treatments, making it a powerful predictive asset in oncology.

The progress of AI in predicting cancer treatment is stalled not by algorithms, but by the data used to train them. Relying solely on static genetic data is insufficient. The critical missing piece is functional, contextual data showing how patient cells actually respond to drugs.

The next frontier in preclinical research involves feeding multi-omics and spatial data from complex 3D cell models into AI algorithms. This synergy will enable a crucial shift from merely observing biological phenomena to accurately predicting therapeutic outcomes and patient responses.

AI is no longer a 'nice-to-have' for radioligand therapies. It is essential for precise patient selection and response monitoring. Without AI-driven confidence in outcomes, the commercial viability, adoption, and reimbursement for these expensive new treatments are at risk, making it a prerequisite for commercial success.